CERO THERAPEUTICS HOLDINGS, INC. Related Party Tax Expense Effect of Change in Allocation Methodology
CERO THERAPEUTICS HOLDINGS, INC. (CERO) had Related Party Tax Expense Effect of Change in Allocation Methodology of $220.00 thousand as of 2023-09-12, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Related Party Transactions
us-gaap:RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology · last filed 2023-11-09
- 2023-09-12: Related Party Tax Expense Effect of Change in Allocation Methodology $220.00K.
| Period end | Related Party Tax Expense Effect of Change in Allocation Methodology |
|---|---|
| 2023-09-12 | $220.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |